Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Alkaline phosphatase less than or equal to 2.5 x ULN

Patients must have normal baseline thyroid function tests (thyroid-stimulating hormone \[TSH\], T3, T4); a history of hypothyroidism and/or hyperthyroidism is allowed, as long as the patient has stable well-controlled thyroid function for a minimum of 2 months

Neuropathy (sensory and motor) less than or equal to grade 1

Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; pregnant women are excluded from this study

Patients must have signed an approved informed consent and authorization permitting the release of personal health information

Patients must be capable of taking and absorbing oral medications; a patient must be clear of the following:

* Any lesion, whether induced by tumor, radiation, or other conditions, which makes it difficult to swallow tablets

* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel

* Active peptic ulcer disease

* Malabsorption syndrome

Any concomitant medications that are associated with a risk of corrected QT (QTc) prolongation and/or Torsades de Pointes should be discontinued or replaced with drugs that do not carry these risks, if possible; patients who must take medication with a risk of possible risk of Torsades de Pointes should be watched carefully for symptoms of QTc prolongation, such as syncope

Strong inhibitors of cytochrome P-450 system (CYP)3A4 are prohibited

Strong inducers of CYP3A4 are prohibited

Concomitant use of agents with narrow therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 is not recommended

Patients who have had previous treatment with pazopanib; patients who have had previous treatment with weekly paclitaxel for recurrent or persistent disease

Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy

Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease

Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease

Patients with clinically significant cardiovascular disease; this includes:

* Uncontrolled hypertension, defined as systolic greater than 140 mm Hg or diastolic greater than 90 mm Hg despite antihypertensive medications

* Congenital long QT syndrome or baseline QTc greater than 480 milliseconds

* Myocardial infarction or unstable angina within 6 months prior to registration

* New York Heart Association (NYHA) class II or greater congestive heart failure

* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication

* This does not include asymptomatic atrial fibrillation with controlled ventricular rate

* Patients who have received prior treatment with an anthracycline (including doxorubicin and/or liposomal doxorubicin) must have an echocardiogram assessment and are excluded if they have an ejection fraction less than 50%

* CTCAE grade 2 or greater peripheral vascular disease (at least brief \[less than 24 hours\] episodes of ischemia managed non-surgically and without permanent deficit)

* History of cardiac angioplasty or stenting within 6 months prior to registration

* History of coronary artery bypass graft surgery within 6 months prior to registration

* Arterial thrombosis within 6 months prior to registration

Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to the first date of study treatment

Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels

Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled with non-enzyme inducing anticonvulsants, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment

History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib

Known human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy

Patients with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:

* Active peptic ulcer disease

* Known gastrointestinal intraluminal metastatic lesions (gastrointestinal serosa metastatic lesions are permitted)

* Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease)

* Patients with clinical symptoms or signs of gastrointestinal obstruction

* Patients who require parenteral hydration and/or nutrition

Patients who are pregnant or nursing

History of hemoptysis in excess of 2.5 mL (½ teaspoon) within 8 weeks prior to first dose of pazopanib

Uncontrolled intercurrent illness including, but not limited to, psychiatric illness/social situations that would limit compliance with study requirements

What this study is about